Company Overview

Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biotechnology company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company’s research and development efforts are concentrated on small-molecule therapies designed to modulate immune and metabolic pathways associated with diseases such as multiple sclerosis, psoriasis, ulcerative colitis, and other immune-mediated disorders. Immunic primarily operates within the biotechnology and pharmaceutical sectors, with its value proposition centered on orally administered therapies intended to offer improved safety, tolerability, and long-term disease management compared with some existing biologic treatments.

The company’s primary revenue driver remains capital raised through equity offerings and financing activities, as Immunic has not yet commercialized products generating recurring product revenue. Its core pipeline includes vidofludimus calcium (IMU-838), a selective immune modulator under clinical evaluation for relapsing multiple sclerosis and other inflammatory indications, along with IMU-856 and IMU-381, which target gastrointestinal barrier function and autoimmune disease pathways, respectively. Immunic traces its origins to the merger between Vital Therapies, Inc. and privately held Immunic AG in 2019, which repositioned the combined entity into an immunology-focused biotechnology company headquartered in the United States with scientific operations linked to Germany.

Business Operations

Immunic operates primarily through research and clinical development activities rather than diversified commercial divisions. Its operations are organized around the advancement of proprietary drug candidates, including IMU-838, IMU-856, and IMU-381. The company generates no material commercial product sales and instead finances operations through public market capital raises, strategic financing transactions, and investor funding. Clinical development activities include Phase 2 and Phase 3 studies focused on autoimmune and inflammatory diseases, with relapsing multiple sclerosis representing a major strategic indication.

The company maintains operations across both the United States and Europe, with scientific and development activities historically connected to Immunic AG in Germany. Immunic controls intellectual property associated with its oral therapeutic candidates and related formulations. Its operational model relies heavily on partnerships with contract research organizations, clinical trial sites, manufacturing vendors, and regulatory consultants to advance drug development programs. Public filings indicate that the company’s business model is focused on progressing clinical assets through regulatory milestones that may support future licensing, commercialization partnerships, or independent commercialization efforts.

Strategic Position & Investments

Immunic’s strategic direction is centered on developing differentiated oral therapies targeting immune and metabolic pathways implicated in chronic inflammatory disease. A major component of this strategy involves advancing vidofludimus calcium (IMU-838) through later-stage clinical trials for multiple sclerosis while also evaluating broader applications in additional autoimmune indications. The company has emphasized selective mechanism-based approaches intended to balance efficacy with long-term safety, particularly in diseases requiring chronic treatment.

The company’s investment priorities remain concentrated on clinical trial execution, regulatory advancement, intellectual property expansion, and pipeline development. Immunic’s portfolio includes IMU-856, designed to restore intestinal barrier function and epithelial integrity, and IMU-381, a next-generation molecule targeting autoimmune disease pathways. Since the reverse merger involving Immunic AG, the company has continued investing in translational medicine capabilities and clinical infrastructure to support global trial expansion. Public disclosures and investor materials indicate that Immunic views oral immunology therapies as a strategic growth area within the broader autoimmune treatment market.

Geographic Footprint

Immunic is headquartered in New York, United States, with significant scientific and operational connections to Germany through its historical integration with Immunic AG. The company’s development activities span North America and Europe, where it conducts clinical research, regulatory interactions, and operational coordination related to its therapeutic programs.

Its clinical studies involve sites across multiple international regions, reflecting the global nature of autoimmune disease drug development. Immunic’s operational footprint is primarily concentrated in the United States and European Union, though its future commercialization strategy could involve broader international markets if regulatory approvals are achieved. The company’s investor base and public market activities are centered in the United States through its Nasdaq listing.

Leadership & Governance

Immunic’s leadership team combines biotechnology, pharmaceutical development, immunology research, and capital markets experience. The company’s governance structure reflects its focus as a clinical-stage biotechnology organization advancing investigational therapies through regulatory development. Management has consistently emphasized disciplined pipeline execution, clinical differentiation, and long-term value creation through immunology innovation.

Key executives include:

• Daniel Vitt, Ph.D. – Chief Executive Officer and President
• Andreas Muehler, M.D. – Chief Medical Officer
• Mark Lucas – Chief Financial Officer
• Hella Kohlhof, Ph.D. – Chief Scientific Officer
• Juergen Zuerbig, Ph.D. – Senior Vice President, Corporate Development and Strategy

Leadership strategy, as reflected in company filings and public communications, prioritizes advancing selective oral therapies with potentially improved safety profiles for chronic autoimmune conditions while maintaining a focused development pipeline supported by clinical and regulatory milestones.